FDA approves new patient‑monitoring features for Abbott’s CardioMEMS HF System
The U.S. Food and Drug Administration cleared enhancements to Abbott Laboratories’ CardioMEMS HF System, adding a CardioGuide HF App that lets heart‑failure patients view pulmonary artery pressure on their phones and receive medication guidance. Abbott said the update expands its digital cardiovascular platform and will help patients and clinicians manage the disease between visits. The approval was announced on October 5, 2026.
Why it matters
The new functionality could increase adoption of Abbott’s remote monitoring technology, potentially boosting sales of the CardioMEMS system. Abbott’s own statement suggests the upgrade strengthens its cardiovascular portfolio, which may improve revenue outlook for the Medical Devices segment.
Key facts
- 1The FDA approved new capabilities for the CardioMEMS HF System, including the CardioGuide HF App, on October 5, 2026. rttnews.com
- 2Patients will be able to see pulmonary artery pressure readings on smartphones for the first time. rttnews.com
- 3Care teams can send personalized medication updates through the CardioGuide HF App. rttnews.com
- 4Abbott noted the system has been in use for more than ten years to monitor heart‑failure patients. rttnews.com
- 5Abbott’s stock was trading at $98.49, up 1.02%, at the time of the report. rttnews.com
- 6Abbott reports a dividend yield of 2.59% and a payout ratio of 80%. gurufocus.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.